research Alopecia areata
Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
Search
for
Sort by
Research
990-1000 / 1000+ results 
research ANDROGENETIC ALOPECIA: A REVIEW OF CURRENT THERAPEUTIC OPTIONS
Effective treatments for hair loss include minoxidil, 5α-reductase inhibitors, and personalized combination therapies.
research A Natural Inhibitor, 1′S-1′-Acetoxychavicol Acetate, Against Testosterone-Induced Alopecia via NADPH Oxidase Regulation
1′S-1′-Acetoxychavicol acetate may help treat hair loss by reducing oxidative stress.
research Reversible exacerbation of obstructive sleep apnea by α1-adrenergic blockade with tamsulosin: A case report
Tamsulosin can worsen sleep apnea in some patients.
research Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
Aromatase inhibitors can cause skin issues, especially with anastrozole and exemestane, so monitoring is important.
research Adverse events with finasteride or dutasteride: FAERS
Lower finasteride doses had more side effects; dutasteride caused back pain; more research needed on post-finasteride syndrome.
research Alopecia Areata in a Dog: Clinical, Dermoscopic and Histological Features
The dog with an Alopecia Areata-like condition showed signs of an autoimmune disease and partially regrew hair without treatment, suggesting dogs could be models for human AA research.
research All-trans retinoic acid induced the differentiation of amelanotic melanocytes of human hair follicle
All-trans retinoic acid helps amelanotic melanocytes in hair follicles develop and produce pigment while reducing their growth.
research Aim to alleviate alopecia areata with newly available agents
New treatments like JAK inhibitors offer hope for better alopecia areata management.
research Proxalutamide (GT0918) Reduces the Rate of Hospitalization in mild-to-moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Two-Arm Parallel Trial
Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.